Researcher

Uğur Şahin

Johannes Gutenberg University Mainz

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · JOURNAL ARTICLE

Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity

Science Advances

Preclinical study in animal models and ex vivo human cells demonstrating mechanism and tolerability of a novel IL-2 variant; supports rationale for clinical evaluation but lacks human efficacy data.

PreliminaryAlexander Muik Uğur Şahin Immunotherapy and Immune Responses

Study details

DesignPreclinical mechanistic and toxicology stud…

InterventionAlb–IL-2var RNA-LNP (engineered IL-2 varian…

ComparatorNot specified; no explicit control arm or c…

JUL 28, 2026 · JOURNAL ARTICLE

MCT4 loss reprograms MC38 tumor environment and potentiates mRNA cancer-vaccine therapy 2305984

The Journal of Immunology

A mechanistic preclinical study in syngeneic mouse tumors demonstrating that MCT4 knockout enhances mRNA vaccine efficacy through immune microenvironment reprogramming, requiring confirmation in larger models and clinical translation.

PromisingElena Klein Fulvia Vascotto Yasemin Ahrberg

Reported

Tumor growthreduced in MC38 Mct4-KO versus wild-type in…

Rejection rateincreased in MC38 Mct4-KO in immunocompeten…

Minimal tumor differencesobserved in immunodeficient mice